Capricor dosed first patient in Phase 3 HOPE-3 trial of CAP-1002 for Duchenne MD

CAPRICOR THERAPEUTICS, INC.

First patient dosed in randomized, double-blind, placebo-controlled HOPE-3 trial enrolling ~70 patients in U.S.
CAP-1002 is a cell therapy for late-stage Duchenne muscular dystrophy; Phase 2 data showed up to 70% slowing of upper limb function loss.
Primary endpoint is Performance of the Upper Limb 2.0; RMAT and Orphan Drug designations support regulatory pathway.
Nippon Shinyaku partnership provides funding and commercialization rights in U.S.; Capricor holds rest-of-world rights.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.